freehire
/
Instylla
Develops resorbable embolic agents for interventional oncology
Subscribe to updates
Discussion
Medical Devices
Biotechnology
instylla.com ↗
Company facts
Founded
2017
Employees
70
Headquarters
United States
Type
Private
Funding
Series C · $21.7M · 2025
Subsidiaries
Embrace Hydrogel Embolic System, Tembo Embolic System